Abstract
The Translocator Protein (18 kDa) (TSPO), previously known as the peripheral benzodiazepine receptor, is widely expressed in glial cells and in peripheral tissues and is involved in a variety of biological processes: steroidogenesis, cell growth and differentiation, apoptosis induction, etc. TSPO basal expression is up-regulated in a number of human pathologies, including a variety of tumors and neuropathologies, such as gliomas and neurodegenerative disorders (Huntingtons and Alzheimers diseases), as well as in various forms of brain injury and inflammation. Furthermore, changes in TSPO receptor levels have been found in anxiety and mood disorders. Nowadays, considerable efforts have been focused on the identification of new TSPO ligands characterized by high-affinity and selectivity. In this review, we report and analyze the main experimental data and the computational procedures and validation methods used for the construction of the TSPO receptor and ligand-based models, describing in detail the most successful results and the new trends.
Keywords: 18 kDa translocator protein (TSPO), 3D-QSAR, computational chemistry, homology model, mutagenesis data, peripheral-type benzodiazepine receptor, pharmacophoric model, virtual screening, glial cells, gliomas, neurodegenerative disorders, high-affinity and selectivity, ligand-based models
Current Topics in Medicinal Chemistry
Title: Computational Studies on Translocator Protein (TSPO) and its Ligands
Volume: 12 Issue: 4
Author(s): Gabriella Ortore, Tiziano Tuccinardi and Adriano Martinelli
Affiliation:
Keywords: 18 kDa translocator protein (TSPO), 3D-QSAR, computational chemistry, homology model, mutagenesis data, peripheral-type benzodiazepine receptor, pharmacophoric model, virtual screening, glial cells, gliomas, neurodegenerative disorders, high-affinity and selectivity, ligand-based models
Abstract: The Translocator Protein (18 kDa) (TSPO), previously known as the peripheral benzodiazepine receptor, is widely expressed in glial cells and in peripheral tissues and is involved in a variety of biological processes: steroidogenesis, cell growth and differentiation, apoptosis induction, etc. TSPO basal expression is up-regulated in a number of human pathologies, including a variety of tumors and neuropathologies, such as gliomas and neurodegenerative disorders (Huntingtons and Alzheimers diseases), as well as in various forms of brain injury and inflammation. Furthermore, changes in TSPO receptor levels have been found in anxiety and mood disorders. Nowadays, considerable efforts have been focused on the identification of new TSPO ligands characterized by high-affinity and selectivity. In this review, we report and analyze the main experimental data and the computational procedures and validation methods used for the construction of the TSPO receptor and ligand-based models, describing in detail the most successful results and the new trends.
Export Options
About this article
Cite this article as:
Ortore Gabriella, Tuccinardi Tiziano and Martinelli Adriano, Computational Studies on Translocator Protein (TSPO) and its Ligands, Current Topics in Medicinal Chemistry 2012; 12(4) . https://dx.doi.org/10.2174/156802612799078667
DOI https://dx.doi.org/10.2174/156802612799078667 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Evaluation of Variances in VEGF-A-D and VEGFR-1-3 Expression in the Ishikawa Endometrial Cancer Cell Line Treated with Salinomycin and Anti-Angiogenic/Lymphangiogenic Effect
Current Pharmaceutical Biotechnology Targeting Opioid and Neurokinin-1 Receptors to Treat Alcoholism
Current Medicinal Chemistry Cancer and Stem Cells
Current Cancer Therapy Reviews Stability Testing During Development of Nanopharmaceuticals
Pharmaceutical Nanotechnology Anti-Cancer/Anti-Tumor
Current Bioactive Compounds Current Status and Perspectives in Peptide Receptor Radiation Therapy
Current Pharmaceutical Design Eph Receptors as Drug Targets: Single-Chain Antibodies and Beyond
Current Drug Targets Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC)
Current Drug Targets Blood-Brain Barrier Penetration and Drug Development from an Industrial Point of View
Current Medicinal Chemistry - Central Nervous System Agents Protein Kinase C and Oxidative Stress in an Animal Model of Mania
Current Neurovascular Research Viral Based Gene Therapy for Prostate Cancer
Current Gene Therapy Uridine Function in the Central Nervous System
Current Topics in Medicinal Chemistry An Epigenetic Approach to Pancreatic Cancer Treatment: The Prospective Role of Histone Deacetylase Inhibitors
Current Cancer Drug Targets Key Epigenetic Events Involved in the Maintenance of Breast Cancer Stem Cells
Current Stem Cell Research & Therapy Recent Clinical Trials of mTOR-Targeted Cancer Therapies
Reviews on Recent Clinical Trials Targeting Death Receptors to Fight Cancer: From Biological Rational to Clinical Implementation
Current Medicinal Chemistry Anti-Epidermal Growth Factor Receptor Strategies to Enhance Radiation Action
Current Medicinal Chemistry - Anti-Cancer Agents EGF-R Small Inhibitors and Anti-EGF-R Antibodies: Advantages and Limits of a New Avenue in Anticancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective
Current Alzheimer Research Insulin Resistance, Oxidative Stress and Cardiovascular Complications: Role of Sirtuins
Current Pharmaceutical Design